ClinicalTrials.gg
CompletedNCT05161390Updated Sep 12, 2025

Study of LM-302 in Patients With Advance Solid Tumors

A Phase 1/2 interventional study of LM-302 Injection in Advanced Solid Tumor, sponsored by LaNova Medicines Zhejiang Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by LaNova Medicines Zhejiang Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
153
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

Read the detailed description

A Phase I/II, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors The study includes phase I (dose escalation) to determine MTD/RP2D and phase II (dose expansion) to assess the preliminary anti-tumor activity, etc..

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

LaNova Medicines Zhejiang Co., Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be enrolled into the study only if they meet all of the following inclusion criteria:

  1. Subjects who are fully informed of the purpose, nature, method and possible adverse reactions of the study, and are willing to participate in the study and sign the document prior to any procedure;
  2. Aged between 18 to 80 years old, male or female when sign the Informed consent form (ICF);
  3. score 0-1;
  4. ≥ 3 months;
  5. Subjects have histological or cytological confirmation of advanced solid tumors, and are intolerable for available standard therapy, or there is no available standard therapy;
  6. Claudin18.2(CLDN18.2) status will be tested by immunohistochemistry (IHC) by central lab, the result must be positive;
  7. At least one evaluable lesion for phase I and one for phase II according to v1.1;
  8. Subjects must have the following organ and marrow function in laboratory tests within 7 days prior to the first dose;
  9. Subjects who are able to well communicate with investigators as well as understand and adhere to the requirements of this study.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study, if they meet any of the following criteria:

  1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-302;
  2. Subjects with anti-tumor treatment within 21 days prior to 1st dosing of LM-302, including radiotherapy, chemotherapy, biotherapy, endocrine therapy and immunotherapy, etc.
  3. Any adverse event from prior anti-tumor therapy has not yet recovered to ≤grade 1 of v5.0;
  4. Peripheral sensory or motor neuropathy ≥ grade 2;
  5. Subjects with uncontrolled tumor-related pain;
  6. Subjects with known central meningeal ;
  7. Subjects with known , stable brain metastasis judged by investigator can be included;
  8. Subjects with uncontrolled third interstitial effusion judged by the investigator to be unsuitable for inclusion;
  9. Subjects with known antibody drug allergy ≥ grade 3;
  10. Subjects who have received the treatment with ADCs targeting to CLDN18.2;
  11. Subjects who were intolerable to the treatment with MMAE based ADCs or anti-CLDN18.2 antibodies are not eligible;
  12. Administrate strong inhibitors/strong inducers of within 14 days prior to 1st dosing of LM-302;
  13. Use of any within 28 days prior to 1st dosing of LM-302;
  14. Subjects with the history of interstitial lung disease or drug-induced interstitial lung disease/pneumonitis;
  15. Subjects who are taking therapeutic doses of anticoagulants such as heparin or vitamin K antagonists (except preventive treatment at a stable dose);
  16. Uncontrolled persistent and recurrent vomiting (e.g. due to gastric outlet obstruction);
  17. Subjects with uncontrolled/severe gastrointestinal hemorrhage, or ulcer within 28 days prior to 1st dosing of LM-302;
  18. Subjects who have received surgical or interventional treatment within 28 days prior to 1st dosing LM-302, with the exception for tumor ,puncture, etc.;
  19. (Limited PhaseⅡ dose expansion)Subjects who have another active which is likely to require treatment, and have the history of another malignancy within 2 years before the 1st dosing LM-302;
  20. Subjects who have severe cardiovascular disease;
  21. Subjects who have uncontrolled or severe illness, including but not limited to ongoing or active infection requiring antibiotics administration;
  22. Subjects who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation, or bone marrow transplantation, or autologous hematopoietic stem cell transplantation;
  23. infection, active and infection;
  24. female who have positive results in pregnancy test before the 1st dosing LM-302 or are lactating;
  25. Subjects who have psychiatric illness or social situations that would preclude study compliance;
  26. Subject who is determined as not eligible to participate in this study by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    LM-302 Dose Escalation at different dose levels

    LM-302 Dose Escalation. 6 dose levels were pre-defined, and the initial accelerated titration followed by the i3+3 design was adopted during phase I.

    Drug: LM-302 Injection

  • Experimental
    LM-302(RP2D) Dose Expansion

    LM-302 Dose Expansion, RP2D will be selected for dose expansion, with the aim to further evaluate the preliminary anti-tumor activity, safety and tolerability, etc.

    Drug: LM-302 Injection

Interventions

  • LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    DLT is defined as a toxicity (adverse event at least possibly related to LM302) occurring during the DLT observation period

    Time frame: Cycle 1 of each cohort. Duration of one cycle is 21 days

  2. Adverse Events and Serious Adverse Events

    The safety profile of LM-302 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: From signing the ICF until 28 days after EOT or accept other anti-cancer therapy

  3. Recommended Phase II Dose (RP2D)

    The RP2D will be determined during the dose expansion stage of the study. RP2D will be determined using available safety and efficacy data

    Time frame: up to 21 days following first dose

  4. Maximum Tolerated Dose (MTD)

    The MTD is defined as the dose of which the toxicity rate during the DLT observation period (21 days after the first administration in cycle 1 on day 1).

    Time frame: up to 21 days following first dose

Secondary outcomes

  1. Area under plasma concentration vs time curve (AUC) for LM-302

    changes in AUC over time in participants with LM-302

    Time frame: Up to finished cycle 5 (each cycle is 21 days)

07

Study locations

1 site
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jan 2025, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2021
First posted
Dec 17, 2021
StartActual
Nov 26, 2021
Primary completionActual
Jan 10, 2025
CompletionActual
Jan 10, 2025
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05161390
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Nov 26, 2021
Primary completion
Jan 10, 2025
Completion
Jan 10, 2025
Last update
Sep 12, 2025

Study contacts

Jin Li
principal investigator · Shanghai East Hospital
Wei Shen
principal investigator · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Yuping Sun
principal investigator · Shandong Province Cancer Hospital
Yanqiao Zhang
principal investigator · The Second Affiliated Hospital of Harbin Medical University
Jianping Xiong
principal investigator · The First Affiliated Hospital of Nanchang University
Wenhui Lou
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tecotabart vedotin

Start the discussion